Actavis to divest four products following Warner Chilcott takeover

Actavis has agreed to divest four products under terms set out by the US Federal Trade Commission pertaining to the company's planned acquisition of Warner Chilcott.

The US regulatory body has approved the imminent takeover, provided that Actavis sells off a number of its assets to Amneal Pharmaceuticals upon the completion of the Warner Chilcott transaction.

Under the terms of the deal agreed with Amneal, Actavis will sell off rights to the currently available therapy Zenchent Fe, as well as the forthcoming generic products norethindrone acetate/ethinyl estradiol, risedronate sodium and norethindrone acetate/ethinyl estradiol.

Having agreed to the sale of these drugs for an undisclosed fee, Actavis will be able to move ahead with the Warner Chilcott merger after it secures approval from the Irish High Court and completes other customary closing conditions.

Originally announced in May 2013, the deal has been valued at around $11 billion (6.81 billion pounds) and will allow Actavis to greatly expand its portfolio, particularly in the field of women's health.